Published Studies
Autoimmune Brain Panel™ Studies
![Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism](https://www.moleculera.com/wp-content/uploads/2024/02/lng-translational-psychiatry.jpg)
Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism
PUBLISHED: TRANSLATIONAL PSYCHIATRY
Study results suggest that the autoimmune targets in the Panel can predict IVIG treatment response in a subset of autism patients.
![Case Report: PANDAS and Persistent Lyme Disease With Neuropsychiatric Symptoms](https://www.moleculera.com/wp-content/uploads/2024/02/lng-pandas-lyme-neuropysch.jpg)
Case Report: PANDAS and Persistent Lyme Disease With Neuropsychiatric Symptoms: Treatment, Resolution, and Recovery
PUBLISHED: FRONTIERS IN PSYCHIATRY
A previously asymptomatic, healthy 7-year-old girl experienced an abrupt onset of several physical, neurological, and psychiatric symptoms increasing in intensity over a 3-week period.
![Autoantibody biomarkers for basal ganglia encephalitis](https://www.moleculera.com/wp-content/uploads/2024/02/lng-frontier-psychiatry.jpg)
Autoantibody biomarkers for basal ganglia encephalitis in Sydenham chorea and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections
PUBLISHED: FRONTIERS IN PSYCHIATRY
Dr. Madeleine Cunningham, co-author, reviews the utilization of antineuronal antibodies (measured with the Panel) as biomarkers for infection-triggered, autoimmune, basal ganglia encephalitis and the significance of the CaMKinase II.
![Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease](https://www.moleculera.com/wp-content/uploads/2024/02/lng-brain-behavior-pub.jpg)
Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
PUBLISHED: BRAIN, BEHAVIOR & IMMUNITY
The Panel results indicate Lyme disease may trigger an autoimmune dysfunction, as elevated neuronal autoantibodies have been associated with persistent symptoms.
![Evaluation of the Cunningham Panel™ in PANDAS and PANS](https://www.moleculera.com/wp-content/uploads/2024/02/lng-panel-evaluation.jpg)
Evaluation of the Cunningham Panel™ in PANDAS and PANS: Changes in antineuronal antibody titers parallel changes in patient symptoms
PUBLISHED: JOURNAL OF NEUROIMMUNOLOGY
Dr. Craig Shimasaki, CEO and President, Moleculera Labs, reviews findings from the study, which describes the sensitivity, specificity and accuracy of the Cunningham Panel™ for patients with PANS and PANDAS.
![](https://www.moleculera.com/wp-content/uploads/2024/02/lng-reports-psychiatry.jpg)
An atypical presentation of Pediatric Acute Neuropsychiatric Syndrome responding to plasmapheresis treatment
PUBLISHED: CASE REPORTS IN PSYCHIATRY
An atypical presentation of Pediatric Acute Neuropsychiatric Syndrome responding to plasmapheresis treatment. Case review: Dr. Shimasaki